World's Best Scientists 2026 revealed!
Award Badge
Medicine
Netherlands
2023

D-Index & Metrics

Medicine

D-Index
143
Citations
94543
World Ranking
1483
National Ranking
50

Research.com Recognitions

  • 2023 - Research.com Medicine in Netherlands Leader Award

Overview

Pieter Sonneveld is affiliated with Erasmus University Rotterdam in the Netherlands. Their research primarily focuses on fields within medicine, biochemistry, genetics, and molecular biology, with a strong specialization in hematology and oncology.

The scientist has contributed extensively to multiple myeloma research and treatments, with notable work also relating to protein degradation and inhibitors, peptidase inhibition and analysis, cancer treatment and pharmacology, chronic lymphocytic leukemia research, amyloidosis diagnosis and treatment, as well as CAR-T cell therapy research.

Frequent co-authors collaborating with Pieter Sonneveld include:

  • Sonja Zweegman
  • Philippe Moreau
  • Niels W.C.J. van de Donk
  • Mario Boccadoro
  • Annemiek Broijl

Their publications appear repeatedly in several scientific journals and venues such as:

  • Blood
  • HemaSphere
  • Clinical Lymphoma Myeloma & Leukemia
  • Journal of Clinical Oncology
  • Leukemia

Recent important papers authored or co-authored by Pieter Sonneveld include:

  • Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma (2023, New England Journal of Medicine)
  • Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up (2021, Annals of Oncology)
  • Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial (2021, The Lancet Oncology)
  • Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study (2020, The Lancet Haematology)
  • Second Revision of the International Staging System (R2-ISS) for Overall Survival in Multiple Myeloma: A European Myeloma Network (EMN) Report Within the HARMONY Project (2022, Journal of Clinical Oncology)

The work by Pieter Sonneveld is positioned within diverse subfields including hematology, molecular biology, oncology, genetics, and immunology, cumulatively accounting for a wide array of scientific contributions across over 700 publications in these areas.

Best Publications

  • International staging system for multiple myeloma.

    Philip R. Greipp;Jesus San Miguel;Brian G.M. Durie;John J. Crowley

  • International uniform response criteria for multiple myeloma

    B. G. M. Durie;J.-L. Harousseau;J. S. Miguel;J. Blade

  • Bortezomib or high-dose dexamethasone for relapsed multiple myeloma

    Paul G. Richardson;Pieter Sonneveld;Michael W. Schuster;David Irwin

  • Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group

    Robert A. Kyle;J. Anthony Child;Kenneth Anderson;Bart Barlogie

  • Autologous Bone Marrow Transplantation as Compared with Salvage Chemotherapy in Relapses of Chemotherapy-Sensitive Non-Hodgkin's Lymphoma

    T Philip;C Guglielmi;A Hagenbeek;R Somers

  • International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma

    Shaji Kumar;Bruno Paiva;Kenneth C. Anderson;Brian Durie

  • Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group

    Antonio Palumbo;Hervé Avet-Loiseau;Stefania Oliva;Henk M. Lokhorst

  • Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma

    Antonio Palumbo;Asher Chanan-Khan;Katja Christina Weisel;Ajay K Nooka

  • Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma

    A. Palumbo;S. V. Rajkumar;M. A. Dimopoulos;P. G. Richardson

  • Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial

    Jesús Fernando San Miguel;Jesús Fernando San Miguel;Katja Weisel;Philippe Moreau;Martha Lacy

  • Bortezomib Induction and Maintenance Treatment in Patients With Newly Diagnosed Multiple Myeloma: Results of the Randomized Phase III HOVON-65/ GMMG-HD4 Trial

    Pieter Sonneveld;Ingo G.H. Schmidt-Wolf;Bronno Van Der Holt;Laila El Jarari

  • Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study

    S. K. Kumar;J. H. Lee;J. J. Lahuerta;G. Morgan

  • International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders

    A. Dispenzieri;R. Kyle;G. Merlini;J. S. Miguel

  • High-dose daunorubicin in older patients with acute myeloid leukemia.

    Bob Löwenberg;Gert J. Ossenkoppele;Wim van Putten;Harry C. Schouten

  • Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management

    R A Kyle;B G M Durie;S V Rajkumar;O Landgren

  • Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study

    Philippe Moreau;Michel Attal;Cyrille Hulin;Bertrand Arnulf

  • Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group

    Pieter Sonneveld;Hervé Avet-Loiseau;Sagar Lonial;Saad Usmani

  • Randomized Phase III Study of Pegylated Liposomal Doxorubicin Plus Bortezomib Compared With Bortezomib Alone in Relapsed or Refractory Multiple Myeloma: Combination Therapy Improves Time to Progression

    Robert Z. Orlowski;Arnon Nagler;Pieter Sonneveld;Joan Bladé

  • Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

    P. Moreau;J. San Miguel;P. Sonneveld;M. V. Mateos

  • ORIGINAL ARTICLE Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma

    A Palumbo;SV Rajkumar;MA Dimopoulos;PG Richardson

Frequent Co-Authors

Sonja Zweegman
Sonja Zweegman Amsterdam UMC
Antonio Palumbo
Antonio Palumbo University of Turin
Meletios A. Dimopoulos
Meletios A. Dimopoulos National and Kapodistrian University of Athens
Michele Cavo
Michele Cavo University of Bologna
Mario Boccadoro
Mario Boccadoro University of Turin
Hartmut Goldschmidt
Hartmut Goldschmidt University Hospital Heidelberg
Roman Hájek
Roman Hájek University of Ostrava
Gareth J. Morgan
Gareth J. Morgan Boston University
Heinz Ludwig
Heinz Ludwig University of Vienna
Jesús F. San Miguel
Jesús F. San Miguel University of Navarra

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those interested in flexible healthcare education options, a variety of online degrees and career pathways are available in the U.S. Many nursing professionals look for accelerated or convenient programs to advance their qualifications while balancing work and personal commitments.

If you are already a registered nurse, the online rn to bsn no clinicals pathway allows you to earn a Bachelor of Science in Nursing without traditional in-person clinical requirements. For nurses aiming for leadership or advanced practice roles, there are several options for both dnp programs online and online dnp programs without clinicals. These can help speed up your career advancement with flexible study models.

Those looking to enter the nursing profession more quickly may consider an lpn accelerated program. These programs provide a fast route to begin working as a licensed practical nurse, sometimes with online options for added convenience.

Exploring these online and accelerated programs can open new doors in healthcare and make it easier to fit your education into a busy life.

Best Scientists Citing Pieter Sonneveld

Trending Scientists

Recently Published Articles